Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Amortizatization of Intangibles: 2013-2024

Historic Amortizatization of Intangibles for ImmunityBio (IBRX) over the last 11 years, with Dec 2024 value amounting to $5.8 million.

  • ImmunityBio's Amortizatization of Intangibles rose 68.62% to $978,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year increase of 91.04%. This contributed to the annual value of $5.8 million for FY2024, which is 5.82% down from last year.
  • Per ImmunityBio's latest filing, its Amortizatization of Intangibles stood at $5.8 million for FY2024, which was down 5.82% from $6.1 million recorded in FY2023.
  • Over the past 5 years, ImmunityBio's Amortizatization of Intangibles peaked at $6.1 million during FY2023, and registered a low of $4.9 million during FY2021.
  • Moreover, its 3-year median value for Amortizatization of Intangibles was $5.9 million (2022), whereas its average is $5.9 million.
  • In the last 5 years, ImmunityBio's Amortizatization of Intangibles rose by 21.46% in 2022 and then fell by 5.82% in 2024.
  • Yearly analysis of 5 years shows ImmunityBio's Amortizatization of Intangibles stood at $5.2 million in 2020, then dropped by 5.26% to $4.9 million in 2021, then rose by 21.46% to $5.9 million in 2022, then grew by 3.03% to $6.1 million in 2023, then dropped by 5.82% to $5.8 million in 2024.